Loading market dashboard
Curative Biotechnology, Inc.
CUBTHealthcareOTCUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania's School of Veterinary Medicine ("PennVet") to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).
Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse stock split (“Reverse Stock Split”) of its common stock at a ratio of 1-for-150. The Reverse Stock Split became effective at 12:00 a.m.
Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse stock split ("Reverse Stock Split") of its common stock at a ratio of 1-for-150.
